Articles - Page 3 - Psychedelic Science Review

Novel chemical variants of ibogaine may offer therapeutic benefits without severe side effects.

The MEQ is a self-report measure that provides insight into a key aspect of the psychedelic experience.

January 06, 2021 - Joshua Falcon, MA

This study is the first of its kind to suggest that psilocybin enhances emotional empathy but does not affect moral behavior.

“I believe one person can produce enough 5-MeO-DMT to supply everyone that would ever want it.”

Researchers at the forefront of psychedelic science put forth their arguments in this important debate.

Changes in brain functioning, new synthesis methods, and psychotherapy dominate this year’s most-cited psilocybin papers.

“Obviously, bureaucracy is not a human being. People have compassion. Bureaucracies don’t always have compassion.' -- Spencer Hawkswell

This study provides meaningful access to some lesser-known magic mushroom compounds and conducts biological testing on them for the first time.

Psychedelic medicine continues to move forward, but minority communities are being left behind.

December 22, 2020 - Alex Criddle, MA

Interestingly, changes in migraine frequency were not correlated with the intensity of the acute psychotropic effects.